Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes... Show more
GNPX saw its Momentum Indicator move above the 0 level on May 29, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned positive. In of the 84 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for GNPX just turned positive on May 20, 2025. Looking at past instances where GNPX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .
GNPX moved above its 50-day moving average on May 29, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where GNPX advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNPX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
GNPX broke above its upper Bollinger Band on May 29, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.401) is normal, around the industry mean (16.282). P/E Ratio (0.000) is within average values for comparable stocks, (59.459). GNPX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.224). Dividend Yield (0.000) settles around the average of (0.039) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (270.467).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GNPX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a developer of molecular therapies for cancer treatment
Industry Biotechnology
A.I.dvisor indicates that over the last year, GNPX has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GNPX jumps, then REVB could also see price increases.
Ticker / NAME | Correlation To GNPX | 1D Price Change % | ||
---|---|---|---|---|
GNPX | 100% | +0.24% | ||
REVB - GNPX | 48% Loosely correlated | -3.41% | ||
HOWL - GNPX | 36% Loosely correlated | -5.47% | ||
APVO - GNPX | 30% Poorly correlated | +0.43% | ||
AXON - GNPX | 30% Poorly correlated | +2.75% | ||
TYRA - GNPX | 30% Poorly correlated | -1.62% | ||
More |